TAAR1 and obesity due to melanocortin 4 receptor deficiency: A considerable body of preclinical evidence supports TAAR1 as a promising target for the treatment of metabolic syndrome and obesity, substance abuse, sleep disorders characterized by changes in REM sleep, and potentially mood and anxiety disorders.